$3.650
+0.500 (+13.71%)終値時点
CAMP のニュース
CAMP のイベント
CAMP4 Therapeutics Receives CTA Approval for CMP-002 Clinical Trial
CAMP4 Therapeutics announced that it has received clinical trial application, or CTA, approval from the regulatory authorities and ethics committees of multiple EU countries to initiate the company's global Phase 1/2 ASCEND clinical trial of CMP-002, a disease-modifying therapeutic candidate for patients with SYNGAP1-related disorder, at trial sites in the European Union.
CAMP4 Reports Q2 Revenue of $1.78M, Below Consensus
Reports Q2 revenue $1.78M, consensus $1.89M. "Having secured regulatory clearance in both Australia and Argentina, we are now focused on initiating our first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1 and are continuing to activate our planned clinical trial in additional jurisdictions," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. "There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives."
CAMP4 Therapeutics Receives Australian Approval to Initiate CMP-002 Clinical Trial
CAMP4 Therapeutics announced that it has received clearance from Australia's Therapeutic Goods Administration, or TGA, and local Human Research Ethics Committee to initiate the Company's Phase 1/2 clinical trial of CMP-002, a disease-modifying therapeutic for SYNGAP1-related disorder.
X4 Pharmaceuticals Appoints Kelly Gold as Independent Director
X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company's board of directors effective July 1, adding strong strategic and financial expertise. Gold will serve as an independent director and member of the audit committee. Gold is currently the CFO at CAMP4 Therapeutics (CAMP).
CAMP4 Reports Q1 Revenue of $1.29M, Exceeding Expectations
Reports Q1 revenue $1.29M, consensus $1.12M. "We have made significant progress year-to-date against our goal of bringing a potential first-in-class treatment for SYNGAP1-related disorder into the clinic," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. "We submitted our first regulatory filing for CMP-002 in Australia which positions us to initiate a global first-in-human Phase 1/2 clinical trial in the second half of 2026. Additional filings with global regulatory agencies are planned throughout 2026. We are also excited to support the ProMMiS study through CURE SYNGAP1 and invest in the foundational science that will further validate our understanding of the natural history of SYNGAP1 and advance meaningful, potentially disease-modifying medicines for all patients affected by this disease."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。